Lijie Xia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lijie Xia has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Jinyao Li
Xinjiang Key Laboratory of Biological Resources and Genetic Engineering College of Life Science and Technology Xinjiang University Urumqi China
17 shared publications Jinyao Li
Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang, China
3 shared publicationsPengfei Yuan
Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang, China
3 shared publicationsShaoqi Yu
Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China
3 shared publicationsZihang Ma
Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China
3 shared publicationsAipire Adila
Xinjiang University
2 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 2005508
Aging-related immune remodeling in ovarian cancer: endocrine cues, cellular senescence, and tumor–immune crosstalk
Ovarian cancer is diagnosed predominantly after menopause, but chronological age, reproductive aging, cellular senescence, immunosenescence, and treatment-related immune dysfunction are frequently conflated. This overlap obscures whether immune phenotypes arise from aging, tumor histotype, therapy, or tumor-derived signals and limits the interpretation of age-associated biomarkers and treatment studies. This narrative review critically evaluates how menopause-associated endocrine remodeling, stromal and cellular senescence, senescence-associated secretory phenotype factors, and IL-6, CXCL8, TNF-α, and IL-1β signaling may interact with the ovarian-cancer immune microenvironment. Histotype-defining genomic pathways, including TP53 alteration, homologous-recombination deficiency, and KRAS–MAPK signaling, are separated from mechanisms plausibly modified by aging. Evidence is interpreted according to four contexts: human ovarian cancer, non-malignant human ovary or pelvic tissue, ovarian cell and animal models, and indirect studies from other cancers or organs; age-resolved findings are considered separately. Human evidence supports marked heterogeneity in immune infiltration, T-cell dysfunction, suppressive myeloid programs, and cytokine signaling, but direct age-resolved clinical evidence remains limited. Tumor-driven immune escape, therapy-induced senescence, and systemic immunosenescence can generate overlapping phenotypes and require explicit separation in study design and interpretation. This review highlights an evidence framework based on histotype, tissue compartment, treatment exposure, functional age, and longitudinal sampling. Progress requires prospective cohorts that include older and frail adults and jointly assess tumor biology, immune state, treatment toxicity, and clinical outcome.
- 5 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 2005508
Open AccessAging-related immune remodeling in ovarian cancer: endocrine cues, cellular senescence, and tumor–immune crosstalk
Ovarian cancer is diagnosed predominantly after menopause, but chronological age, reproductive aging, cellular senescence, immunosenescence, and treatment-related immune dysfunction are frequently conflated. This overlap obscures whether immune phenotypes arise from aging, tumor histotype, therapy, or tumor-derived signals and limits the interpretation of age-associated biomarkers and treatment studies. This narrative review critically evaluates how menopause-associated endocrine remodeling, stromal and cellular senescence, senescence-associated secretory phenotype factors, and IL-6, CXCL8, TNF-α, and IL-1β signaling may interact with the ovarian-cancer immune microenvironment. Histotype-defining genomic pathways, including TP53 alteration, homologous-recombination deficiency, and KRAS–MAPK signaling, are separated from mechanisms plausibly modified by aging. Evidence is interpreted according to four contexts: human ovarian cancer, non-malignant human ovary or pelvic tissue, ovarian cell and animal models, and indirect studies from other cancers or organs; age-resolved findings are considered separately. Human evidence supports marked heterogeneity in immune infiltration, T-cell dysfunction, suppressive myeloid programs, and cytokine signaling, but direct age-resolved clinical evidence remains limited. Tumor-driven immune escape, therapy-induced senescence, and systemic immunosenescence can generate overlapping phenotypes and require explicit separation in study design and interpretation. This review highlights an evidence framework based on histotype, tissue compartment, treatment exposure, functional age, and longitudinal sampling. Progress requires prospective cohorts that include older and frail adults and jointly assess tumor biology, immune state, treatment toxicity, and clinical outcome.
- Open Access
- 12 June 2026
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 267, 115894
Tumor cell membrane-camouflaged biomimetic liposomes for targeted delivery of phytosphingosine with enhanced anti-lung cancer activity
- 12 June 2026
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 267, 115894
Open AccessTumor cell membrane-camouflaged biomimetic liposomes for targeted delivery of phytosphingosine with enhanced anti-lung cancer activity
- 15 May 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Instrumentation and Measurement
- Vol. 75 (00189456) , 9520515
Hierarchical Cross-Modal Fusion Model for Field Vehicle Classification
Field Vehicle classification is an important task for unattended ground sensor systems. This paper proposes a multimodal fusion-based classification method. Based on field measurement data collected in field environments, each signal sample contains continuous acoustic and seismic signals together with discrete image signals, which leads to information imbalance between the image modality and the acoustic-seismic modalities. To address this issue in multimodal fusion, a Hierarchical Cross-Modal Fusion (HCMF) method is proposed. First, shallow and deep convolutional features are extracted for each modality using a convolutional network. Subsequently, a two-level fusion strategy is performed using the proposed HCMF framework. In the first-level fusion, three intra-modal transformer models are employed to fuse the two convolutional features within each modality, and the outputs of the three modalities are combined into a hybrid modality feature through confidence-weighted fusion. In the second-level fusion, a inter-modal transformer model processes the hybrid modality feature to enable cross-modal information interaction, and the resulting representation is used for classification. Based on a small-scale dataset constructed from field measurement data, a series of experiments are conducted, including model generalization evaluation, ablation studies, modality absence analysis, and algorithm comparisons. Experimental results demonstrate that the proposed model exhibits generalization capability, achieving a macro F1-score of 98.45% with 1.77 million parameters and 81.19 million FLOPs. The proposed method effectively balances classification performance and computational complexity, providing a potential solution for embedded applications in field vehicle classification.
- 15 May 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Instrumentation and Measurement
- Vol. 75 (00189456) , 9520515
Hierarchical Cross-Modal Fusion Model for Field Vehicle Classification
Field Vehicle classification is an important task for unattended ground sensor systems. This paper proposes a multimodal fusion-based classification method. Based on field measurement data collected in field environments, each signal sample contains continuous acoustic and seismic signals together with discrete image signals, which leads to information imbalance between the image modality and the acoustic-seismic modalities. To address this issue in multimodal fusion, a Hierarchical Cross-Modal Fusion (HCMF) method is proposed. First, shallow and deep convolutional features are extracted for each modality using a convolutional network. Subsequently, a two-level fusion strategy is performed using the proposed HCMF framework. In the first-level fusion, three intra-modal transformer models are employed to fuse the two convolutional features within each modality, and the outputs of the three modalities are combined into a hybrid modality feature through confidence-weighted fusion. In the second-level fusion, a inter-modal transformer model processes the hybrid modality feature to enable cross-modal information interaction, and the resulting representation is used for classification. Based on a small-scale dataset constructed from field measurement data, a series of experiments are conducted, including model generalization evaluation, ablation studies, modality absence analysis, and algorithm comparisons. Experimental results demonstrate that the proposed model exhibits generalization capability, achieving a macro F1-score of 98.45% with 1.77 million parameters and 81.19 million FLOPs. The proposed method effectively balances classification performance and computational complexity, providing a potential solution for embedded applications in field vehicle classification.
- Open Access
- 5 February 2026
- Published by Elsevier in International Journal of Pharmaceutics: X
- Vol. 11, 100503
Brain-targeted delivery of siRNA via non-viral delivery systems, the therapeutic strategy for Alzheimer's disease—Unveiling challenges and prospects
- 5 February 2026
- Published by Elsevier in International Journal of Pharmaceutics: X
- Vol. 11, 100503
Open AccessBrain-targeted delivery of siRNA via non-viral delivery systems, the therapeutic strategy for Alzheimer's disease—Unveiling challenges and prospects
- Open Access
- 27 October 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1644498
Artemisia absinthium L. ethanol extract inhibits the growth of gastrointestinal cancer cells by inducing apoptosis and mitochondria-dependent pathway
Objectives: Artemisia absinthium L. has a long history in the treatment of gastrointestinal cancer (GIC), but its molecular mechanisms remain unclear. Materials and methods: We identified and validated the active components and key targets in A. absinthium for the treatment of GIC by LC-MS and Network analysis. The antitumor effect of A. absinthium ethanol extract (AAEM-V) against gastrointestinal tract cancer in vitro and in vivo as well as the anticancer activity of the active ingredient, Luteolinidin, were further evaluated. Results: AAEM-V exhibited good anticancer activity in vitro and in vivo . The active ingredient Luteolinidin was taken to intersect with the targets of gastric and colorectal cancers, and 69 common targets were identified. A total of three core targets, SRC, EGFR, and AKT1, were screened according to PPI and molecularly docked with Luteolinidin, and it was found that their binding played a key role in the treatment of tumors. Meanwhile, its active ingredient Luteolinidin was found to induce ROS proliferation to promote apoptosis and prevent cells from entering S phase. Conclusion: These findings not only explored the anti-gastrointestinal cancer chemical properties of A. absinthium , but also provided a new research direction for the active ingredients and mechanism of action of traditional Chinese medicine.
- 27 October 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1644498
Open AccessArtemisia absinthium L. ethanol extract inhibits the growth of gastrointestinal cancer cells by inducing apoptosis and mitochondria-dependent pathway
Objectives: Artemisia absinthium L. has a long history in the treatment of gastrointestinal cancer (GIC), but its molecular mechanisms remain unclear. Materials and methods: We identified and validated the active components and key targets in A. absinthium for the treatment of GIC by LC-MS and Network analysis. The antitumor effect of A. absinthium ethanol extract (AAEM-V) against gastrointestinal tract cancer in vitro and in vivo as well as the anticancer activity of the active ingredient, Luteolinidin, were further evaluated. Results: AAEM-V exhibited good anticancer activity in vitro and in vivo . The active ingredient Luteolinidin was taken to intersect with the targets of gastric and colorectal cancers, and 69 common targets were identified. A total of three core targets, SRC, EGFR, and AKT1, were screened according to PPI and molecularly docked with Luteolinidin, and it was found that their binding played a key role in the treatment of tumors. Meanwhile, its active ingredient Luteolinidin was found to induce ROS proliferation to promote apoptosis and prevent cells from entering S phase. Conclusion: These findings not only explored the anti-gastrointestinal cancer chemical properties of A. absinthium , but also provided a new research direction for the active ingredients and mechanism of action of traditional Chinese medicine.
- Open Access
Artemisia absinthium L. Extract Targeting the JAK2/STAT3 Pathway to Ameliorate Atherosclerosis
Artemisia absinthium L. contributes to ecological stabilization in arid regions through its deep root system for sand fixation and soil microenvironment modulation, thereby effectively mitigating desertification. Total terpenoids have been extracted from A. absinthium (AATP) and found to have antioxidant and anti-inflammatory activities. Terpenoids are a class of natural products derived from methyl hydroxypropanoic acid, for which their structural units consist of multiple isoprene (C5) units. They are one of the largest and most structurally diverse classes of natural compounds. However, there are still large gaps in knowledge regarding their exact biological activities and effects. Atherosclerosis (AS) is a prevalent cardiovascular disease marked by the chronic inflammation of the vascular system, and lipid metabolism plays a key role in its pathogenesis. This study determined the extraction and purification processes of AATP through single-factor experiments and response surface optimization methods. The purity of AATP was increased from 20.85% ± 0.94 before purification to 52.21% ± 0.75, which is 2.5 times higher than before purification. Studies have shown that the total terpenoids of A. absinthium significantly reduced four indices of serum lipids in atherosclerosis (AS) rats, thereby promoting lipid metabolism, inhibiting inflammatory processes, and hindering aortic wall thickening and hepatic fat accumulation. It is known from network pharmacology studies that AATP regulates the Janus kinase/signal transducer (JAK/STAT) signaling axis. Molecular docking studies have indicated that the active component of AATP effectively binds to Janus kinase (JAK2) and signal transducer (STAT3) target proteins. The results indicate that AATP can inhibit the release of pro-inflammatory mediators (such as reactive oxygen species (ROS)) in LPS-induced RAW264.7 macrophages. It also inhibits the M1 polarization of RAW264.7 macrophages. Protein immunoblotting analysis revealed that it significantly reduces the phosphorylation levels of Janus kinase (JAK2) and the signal transducer and activator of transcription 3 (STAT3). Research indicates that the active components in A. absinthium may exert anti-atherosclerotic effects by regulating lipid metabolism and inhibiting inflammatory responses. It holds potential value for development as a functional food or drug for the prevention and treatment of atherosclerosis.
Open AccessArtemisia absinthium L. Extract Targeting the JAK2/STAT3 Pathway to Ameliorate Atherosclerosis
Artemisia absinthium L. contributes to ecological stabilization in arid regions through its deep root system for sand fixation and soil microenvironment modulation, thereby effectively mitigating desertification. Total terpenoids have been extracted from A. absinthium (AATP) and found to have antioxidant and anti-inflammatory activities. Terpenoids are a class of natural products derived from methyl hydroxypropanoic acid, for which their structural units consist of multiple isoprene (C5) units. They are one of the largest and most structurally diverse classes of natural compounds. However, there are still large gaps in knowledge regarding their exact biological activities and effects. Atherosclerosis (AS) is a prevalent cardiovascular disease marked by the chronic inflammation of the vascular system, and lipid metabolism plays a key role in its pathogenesis. This study determined the extraction and purification processes of AATP through single-factor experiments and response surface optimization methods. The purity of AATP was increased from 20.85% ± 0.94 before purification to 52.21% ± 0.75, which is 2.5 times higher than before purification. Studies have shown that the total terpenoids of A. absinthium significantly reduced four indices of serum lipids in atherosclerosis (AS) rats, thereby promoting lipid metabolism, inhibiting inflammatory processes, and hindering aortic wall thickening and hepatic fat accumulation. It is known from network pharmacology studies that AATP regulates the Janus kinase/signal transducer (JAK/STAT) signaling axis. Molecular docking studies have indicated that the active component of AATP effectively binds to Janus kinase (JAK2) and signal transducer (STAT3) target proteins. The results indicate that AATP can inhibit the release of pro-inflammatory mediators (such as reactive oxygen species (ROS)) in LPS-induced RAW264.7 macrophages. It also inhibits the M1 polarization of RAW264.7 macrophages. Protein immunoblotting analysis revealed that it significantly reduces the phosphorylation levels of Janus kinase (JAK2) and the signal transducer and activator of transcription 3 (STAT3). Research indicates that the active components in A. absinthium may exert anti-atherosclerotic effects by regulating lipid metabolism and inhibiting inflammatory responses. It holds potential value for development as a functional food or drug for the prevention and treatment of atherosclerosis.
- Open Access
- 17 April 2025
- Published by Elsevier in Industrial Crops and Products
- Vol. 229
Targeted discovery of multi-action bioactive compounds from Capparis spinosa L. for mitigating diabetic cardiomyopathy
- 17 April 2025
- Published by Elsevier in Industrial Crops and Products
- Vol. 229
Open AccessTargeted discovery of multi-action bioactive compounds from Capparis spinosa L. for mitigating diabetic cardiomyopathy
- Open Access
- 13 December 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (12) , 1591
A Zeolitic Imidazolate Framework-Based Antimicrobial Peptide Delivery System with Enhanced Anticancer Activity and Low Systemic Toxicity
Background: The clinical efficacies of anticancer drugs are limited by non-selective toxic effects on healthy tissues and low bioavailability in tumor tissue. Therefore, the development of vehicles that can selectively deliver and release drugs at the tumor site is critical for further improvements in patient survival. Methods: We prepared a CEC nano-drug delivery system, CEC@ZIF-8, with a zeolite imidazole framework-8 (ZIF-8) as a carrier, which can achieve the response of folate receptor (FR). We characterized this system in terms of morphology, particle size, zeta potential, infrared (IR), x-ray diffraction (XRD), and transcriptome analysis, and examined the in vitro cytotoxicity and cellular uptake properties of CEC@ZIF-8 using cervical cancer cells. Lastly, we established a TC-1 tumor-bearing mouse model and evaluated its in vivo anti-cervical cancer activity. Results: The CEC@ZIF-8 nano-delivery system had favorable biocompatibility, heat stability, and pH responsiveness, with a CEC loading efficiency of 12%, a hydrated particle size of 174 ± 5.8 nm, a zeta potential of 20.57 mV, and slow and massive drug release in an acidic environment (pH 5.5), whereas release was 6% in a neutral environment (pH 7.4). At the same time, confocal imaging and cell viability assays demonstrated greater intracellular accumulation and more potent cytotoxicity against cancer cells compared to free CEC. The mechanism was analyzed by a series of transcriptome analyses, which revealed that CEC@ZIF-8 NPs differentially regulate the expression levels of 1057 genes in cancer cells, and indicated that the enriched pathways were mainly cell cycle and apoptosis-related pathways via the enrichment analysis of the differential genes. Flow cytometry showed that CEC@ZIF-8 NPs inhibited the growth of HeLa cells by arresting the cell cycle at the G0/G1 phase. Flow cytometry also revealed that CEC@ZIF-8 NPs induced greater apoptosis rates than CEC, while unloaded ZIF-8 had little inherent pro-apoptotic activity. Furthermore, the levels of reactive oxygen species (ROS) were also upregulated by CEC@ZIF-8 NPs while ROS inhibitors and caspase inhibitors reversed CEC@ZIF-8 NPs-induced apoptosis. Finally, CEC@ZIF-8 NPs also reduced the growth rate of xenograft tumors in mice without the systemic toxicity observed with cisplatin treatment. Conclusions: The CEC@ZIF-8 nano-drug delivery system significantly enhanced the anti-cervical cancer effect of CEC both in vivo and in vitro, providing a more promising drug delivery system for clinical applications and tumor management. At the same time, this work demonstrates the clinical potential of CEC-loaded ZIF-8 nanoparticles for the selective destruction of tumor tissues.
- 13 December 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (12) , 1591
Open AccessA Zeolitic Imidazolate Framework-Based Antimicrobial Peptide Delivery System with Enhanced Anticancer Activity and Low Systemic Toxicity
Background: The clinical efficacies of anticancer drugs are limited by non-selective toxic effects on healthy tissues and low bioavailability in tumor tissue. Therefore, the development of vehicles that can selectively deliver and release drugs at the tumor site is critical for further improvements in patient survival. Methods: We prepared a CEC nano-drug delivery system, CEC@ZIF-8, with a zeolite imidazole framework-8 (ZIF-8) as a carrier, which can achieve the response of folate receptor (FR). We characterized this system in terms of morphology, particle size, zeta potential, infrared (IR), x-ray diffraction (XRD), and transcriptome analysis, and examined the in vitro cytotoxicity and cellular uptake properties of CEC@ZIF-8 using cervical cancer cells. Lastly, we established a TC-1 tumor-bearing mouse model and evaluated its in vivo anti-cervical cancer activity. Results: The CEC@ZIF-8 nano-delivery system had favorable biocompatibility, heat stability, and pH responsiveness, with a CEC loading efficiency of 12%, a hydrated particle size of 174 ± 5.8 nm, a zeta potential of 20.57 mV, and slow and massive drug release in an acidic environment (pH 5.5), whereas release was 6% in a neutral environment (pH 7.4). At the same time, confocal imaging and cell viability assays demonstrated greater intracellular accumulation and more potent cytotoxicity against cancer cells compared to free CEC. The mechanism was analyzed by a series of transcriptome analyses, which revealed that CEC@ZIF-8 NPs differentially regulate the expression levels of 1057 genes in cancer cells, and indicated that the enriched pathways were mainly cell cycle and apoptosis-related pathways via the enrichment analysis of the differential genes. Flow cytometry showed that CEC@ZIF-8 NPs inhibited the growth of HeLa cells by arresting the cell cycle at the G0/G1 phase. Flow cytometry also revealed that CEC@ZIF-8 NPs induced greater apoptosis rates than CEC, while unloaded ZIF-8 had little inherent pro-apoptotic activity. Furthermore, the levels of reactive oxygen species (ROS) were also upregulated by CEC@ZIF-8 NPs while ROS inhibitors and caspase inhibitors reversed CEC@ZIF-8 NPs-induced apoptosis. Finally, CEC@ZIF-8 NPs also reduced the growth rate of xenograft tumors in mice without the systemic toxicity observed with cisplatin treatment. Conclusions: The CEC@ZIF-8 nano-drug delivery system significantly enhanced the anti-cervical cancer effect of CEC both in vivo and in vitro, providing a more promising drug delivery system for clinical applications and tumor management. At the same time, this work demonstrates the clinical potential of CEC-loaded ZIF-8 nanoparticles for the selective destruction of tumor tissues.
- Open Access
- 26 November 2024
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 247, 114411
ROS-responsive supramolecular antimicrobial peptides-based nanoprodrugs for cervical cancer therapy
- 26 November 2024
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 247, 114411
Open AccessROS-responsive supramolecular antimicrobial peptides-based nanoprodrugs for cervical cancer therapy
- Open Access
- 13 August 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 178, 117119
Non-viral vectors combined delivery of siRNA and anti-cancer drugs to reverse tumor multidrug resistance
- 13 August 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 178, 117119
Open AccessNon-viral vectors combined delivery of siRNA and anti-cancer drugs to reverse tumor multidrug resistance